|
Originally published In Press as doi:10.1074/jbc.M003652200 on July 27, 2000
J. Biol. Chem., Vol. 275, Issue 41, 31689-31694, October 13, 2000
From Malate Dehydrogenase to Phenyllactate Dehydrogenase
INCORPORATION OF UNNATURAL AMINO ACIDS TO GENERATE AN IMPROVED
ENZYME-CATALYZED ACTIVITY*
S. Kirk
Wright ,
Michelle M.
Kish, and
Ronald E.
Viola§
From the the Department of Chemistry, University of Akron,
Akron, Ohio 44325
Received for publication, April 28, 2000, and in revised form, July 21, 2000
 |
ABSTRACT |
Malate dehydrogenase (MDH) from Escherichia
coli is highly specific for its keto acid substrate. The
placement of the active site-binding groups in MDH effectively
discriminates against both the shorter and the longer keto dicarboxylic
acids that could potentially serve as alternative substrates. A notable
exception to this specificity is the alternative substrate
phenylpyruvate. This aromatic keto acid can be reduced by MDH, albeit
at a somewhat slower rate and with greatly diminished affinity, despite
the presence of several substrate-binding arginyl residues and the absence of a hydrophobic pocket in the active site. The specificity of
MDH for phenylpyruvate has now been enhanced, and that for the
physiological substrate oxaloacetate has been diminished, through the
replacement of one of the binding arginyl residues with several
unnatural alkyl and aryl amino acid analogs. This approach, called
site-specific modulation, incorporates systematic structural variations
at a site of interest. Molecular modeling studies have suggested a
structural basis for the affinity of native MDH for phenylpyruvate and
a rationale for the improved catalytic activity that is observed with
these new, modified phenyllactate dehydrogenases.
 |
INTRODUCTION |
An approach for the site-specific incorporation of any unnatural
amino acid analog into an enzyme is being examined with a method called
site-specific modulation that utilizes the inherent reactivity of
cysteine to generate systematic structural variations at a site of
interest. This approach combines the strength of site-directed
mutagenesis (absolute specificity) with the wide range of structural
analogs that can be accessed through chemical modifications. The
earlier work in this area focused primarily on the regeneration of
lysine analogs to restore activity in aspartase aminotranferase (1, 2)
and ribulose bisphosphate carboxylase/oxygenase (3) or on arginine
analogs to test the role of this functional group in the specificity of
glutamine synthetase (4). Instead of the limited goal of replacing the
target amino acid with an analog that mimics the natural amino acid,
the aim of this approach is to systematically alter the enzyme active
site groups that are responsible for substrate recognition and binding.
In this way new catalysts can be generated with specificities that are designed for reactions of interest.
Malate dehydrogenase catalyzes the oxidation of malate to oxaloacetate
(OAA)1 with the concomitant
reduction of NAD+ to NADH. This enzyme is highly specific
for its natural substrates, malate and OAA, and efficiently
discriminates against both shorter and longer dicarboxylic acids.
Examination of the crystal structure provides an explanation for the
substrate selectivity that is observed with this enzyme (5). Both
malate and OAA are proposed to be bound at each end through
electrostatic interactions between the two substrate carboxyl groups
and two arginyl residues (Arg-81 and Arg-153) that are positioned to
interact precisely with a four-carbon dicarboxylic acid (Fig. 1).
Lactate dehydrogenase (LDH) and malate dehydrogenase (MDH) are very
similar 2-keto acid dehydrogenases that catalyze related reactions by
an equivalent mechanism (5, 6). Despite the overall structural
similarities the sequence homology between these functionally related
enzyme families is quite low. However, the functional active site amino
acids are highly conserved between these enzyme families (7). To
examine the specificity of LDH the active site, which is normally
specific for pyruvate, has been redesigned to use phenylpyruvate as a
substrate by mutagenically switching sections of a mobile loop that is
responsible for substrate specificity (8). Mutagenic replacement of an
important active site residue in LDH (Gln-102) has also lead to an
enzyme form that will utilize phenylpyruvate, with the
kcat/Km for phenylpyruvate
improved by a factor of 100 over that of the native enzyme (9). Native
MDH has also been shown to be capable of catalyzing the reduction of
phenylpyruvate to phenyllactate, although at a rate that is
substantially reduced when compared with its physiological substrate
OAA (10).
With the observation that MDH can use phenylpyruvate as an alternative
substrate, and starting with the mutagenic studies on LDH, our goal was
to expand the redesign options that are available by selectively
incorporating unnatural amino acids that could potentially enhance the
binding and catalysis of phenylpyruvate, using malate dehydrogenase as
a structural scaffold. We report here the use of site-specific
modulation to convert malate dehydrogenase into an efficient
phenyllactate dehydrogenase.
 |
EXPERIMENTAL PROCEDURES |
Materials--
The pEM 6 plasmid containing the mdh
gene was a gift from Dr. N.C. Furumo (Eastern Illinois University). All
restriction endonucleases and molecular weight markers were purchased
from New England Biolabs. Electrophoresis grade agarose was purchased
from SeaChem. Primers were obtained from Integrated DNA Technologies,
Inc. Native Pfu DNA polymerase and the polymerase chain
reaction optimization kit were purchased from Stratagene. Affi-blue
resin was purchased from Bio-Rad. Phenyllactate, 2-bromopropane,
1-bromo-2-methylpropane, benzyl bromide, and 4-fluorobenzyl bromide
were obtained from Aldrich. 4-Aminobenzyl alcohol was from Lancaster,
and all other chemicals were purchased from Sigma. Purification of MDH
was performed according to a previously published scheme (11).
Enzyme and Protein Assays--
The activity of malate
dehydrogenase was determined spectrophotometrically by measuring either
the formation or the disappearance of NADH (E340 = 6.22 mM 1 cm 1). Standard assay
conditions were as follows: 50 mM buffer, 2 mM
EDTA, 100 mM KCl, and variable concentrations of the
hydroxy or keto acid substrates in the presence of saturating levels of coenzyme (either 0.15 mM NADH or 7 mM
NAD+) (12). Each reaction was initiated by the addition of
enzyme, and the kinetic data were fitted by using an Enzyme Kinetics
software package, adapted from the programs of Cleland (13), to obtain the kinetic parameters. Protein concentration was determined by the
Bradford method (14) using bovine serum albumin as a standard.
Mutagenic Method--
Site-directed mutagenesis was carried out
by using recombinant circle polymerase chain reaction (15, 16), which
utilizes four primers (two mutagenic and two nonmutagenic) that are
designed to generate double-stranded, linear DNA molecules with blunt
ends. Once combined, denatured, and reannealed, this linear DNA
produces double-stranded DNA with discrete cohesive single-stranded
ends, in addition to the previously made blunt ends. However, only the former polymerase chain reaction product containing the mutation in
each strand will anneal to form recombinant circles of DNA that can
effectively mimic circular DNA that is necessary to be transformed into
TG-1 cells. This method was successfully utilized for the production of
the linear DNA, which then allowed the creation of a R81S mutagenic
site (SnaBI) within the malate dehydrogenase gene, where the
mismatched bases to create the mutagenic replacements are shown in
lowercase and the newly introduced restriction endonuclease site is
underlined: R81S, CG TAC Gta GT; and R81C, CG TAC Gtt GT.
The process was then repeated using the R81S DNA as the template, with
any subsequent mutations at position 81 destroying the newly created
SnaBI site. Initial screening for the presence of mutagenic colonies was accomplished by restriction enzyme mapping and was further
verified by DNA sequencing.
Chemical Modulation--
Chemical modification of R81C MDH with
the various amino acid analog reagents was carried out in 250 mM borate buffer, pH 8.75, using an enzyme concentration of
4 mg/ml and a reagent concentration of 40 mM. The reagents
were either obtained as the halides or were converted to the halides as
described previously (17). The enzyme was typically incubated with each
of the reagents for about 8 h at 4 °C. The extent of
modification was followed by examining the free cysteine content,
determined by the method of Ellman (18) or by several alternative
fluorescent or enzyme-linked methods (19). In each case one (±0.2)
cysteine was modified in the R81C mutant, with no cysteine modification
observed in the native enzyme. After completion of the modification,
the reaction was terminated by the removal of excess reagent by Amicon
Centricon-30 filtration, with three successive washes with the standard
assay buffer.
Molecular Modeling--
Molecular modeling studies were carried
out on a Silicon Graphics O2 computer using the
Sybyl (version 6.5) software package (Tripos, Inc.). Coordinates of
native MDH were obtained as a Protein Data Bank file and the
program Flexidock was used to position the substrates into the enzyme
active site before energy minimization. This algorithm fixes the
position of the protein backbone atoms and bonds and allows flexibility
in the side chain and substrate atoms and bonds. The force field
calculations take into account van der Waals', electrostatic,
torsional, and constraint energy terms.
 |
RESULTS |
Production of R81C MDH--
To screen colonies for mutated MDH,
the production of the R81C mutant was carried out in two stages.
Initially, a serine was introduced at position 81 in place of the
native arginine. This was accomplished as described under
"Experimental Procedures" by a two base change that also created an
SnaBI restriction endonuclease site. After isolation of the
R81S mutant a second round of mutagenesis was used to replace this
serine with a cysteine, thus destroying the newly created
SnaBI site. Restriction mapping for the presence and then
the absence of this site was used to identify mutagenic colonies.
Subsequent DNA sequencing, covering at least 800 bases centered around
this position, confirmed the mutations that were made.
Kinetic Characterization of Arg-81 MDH Mutants--
The R81C
mutant was purified by using the standard purification procedure (11).
The kinetic parameters were determined for this mutant and compared
with those of the native enzyme (Table I). Replacement of Arg-81 with Cys
results in a 3-fold decrease in kcat, whereas
essentially no change is observed in the Michaelis constant for OAA,
leading to a modest 3-fold decrease in
kcat/Km. Hydroxypyruvate, in
which the -carboxyl group of OAA is replaced by a hydroxyl group, is
a poor alternative substrate for the native enzyme, with a
kcat/Km value that is more
than 3 orders of magnitude lower than that of OAA. Surprisingly,
phenylpyruvate, in which the -carboxyl group has been replaced with
a phenyl ring, is also a substrate for MDH with a
kcat and a
kcat/Km that are comparable
with those of hydroxypyruvate. The R81C mutant has a
kcat with phenylpyruvate that is further
decreased by a factor of 2 but has a lower Km that
leads to a kcat/Km that is
improved by 4-fold compared with the native enzyme (Table I). The
product of this reaction, phenyllactate, is also an alternative substrate in the reverse reaction; however, precise kinetic parameters are difficult to determine because of an initial time lag that is
observed under all of the substrate concentrations and pH values that
were examined.
Removal of the bulky arginyl side chain should provide an expanded
binding pocket that should allow the accommodation of larger substrates
into the active site. 2-Ketoglutarate, the 5-carbon homolog of OAA, is
a poor alternative substrate for the native enzyme with a
kcat that is only 2% and a
kcat/Km that is 4-orders of
magnitude lower than OAA (Table I). However, instead of seeing an
improvement with this substrate, the R81C mutant shows no detectable
activity with 2-ketoglutarate nor with several other potential
alternative substrates including 2-ketocaproate, the 6-carbon homolog.
In an attempt to provide an improved binding site and enhanced kinetics
for phenylpyruvate as an alternative substrate the arginine at position
81 was replaced with a phenylalanine. The kcat
for phenylpyruvate decreases with the R81F mutant, but by less than a
factor of 2, whereas the Km value for this substrate
shows a 3-fold improvement, resulting in a 2-fold enhancement in
kcat/Km for phenylpyruvate
compared with the native enzyme. The introduction of an aromatic side
chain at this position also results in a decrease in
kcat for the physiological substrate OAA to
about 7% that of the native enzyme. However the Km value for OAA is not affected by this mutation
(Table II).
Chemical Modulation--
To create a significant alteration in the
specificity of MDH, it appears necessary to introduce a wider range of
new functional groups into the active site to modify the substrate
specificity. To this end the R81C mutant was chemically modulated by
using several different hydrophobic aliphatic and aromatic amino acid analog reagents. In each case, through the time course of the modification reaction, there is an observed decrease of approximately one free cysteine/enzyme subunit. This decrease is consistent with the
selective modification of the introduced thiolate at position 81. The
native enzyme, which contains three cysteines/subunit, is not modified
to any significant extent by these reagents under the reaction
conditions. This lack of reactivity was anticipated because these
cysteines are nearly completely buried in the native MDH structure (5).
The kinetic parameters for these modified enzymes were determined and
were compared with both the native enzyme and to the unmodified mutant enzyme.
Modulation of R81C with either 2-bromopropane or
1-bromo-2-methylpropane leads to the selective incorporation of a
propyl or a 2-methylpropyl group at position 81. The resulting modified enzymes have essentially the same kcat with
phenylpyruvate as the unmodified R81C mutant. However, the
Km values for phenylpyruvate with these modified
enzymes increase by factors of 2 and 3, respectively (Table II).
Treatment of R81C MDH with benzyl bromide introduces a benzyl group at
position 81, and this modified enzyme has a kcat
with phenylpyruvate of 450 s 1 compared with 120 s 1 for the R81C mutant and 200 s 1 for the
native enzyme. The benzyl-modified enzyme has a modest increase in
Km when compared with the R81C mutant but has a
5-fold decrease when compared with the native enzyme, resulting in an
overall improvement in
kcat/Km for phenylpyruvate by
a factor of 10 (Table II). Introduction of either an alkyl or an aryl
group at position 81 leads to a further decrease in both
kcat and
kcat/Km for OAA when compared
with the unmodified R81C mutant, to values that are more than 2 orders of magnitude lower than those with the native enzyme.
To examine the importance of the aromatic benzyl group in substrate
recognition, the R81C mutant was modified with the related cyclohexyl
derivative. A modest 4-fold decrease is observed in the
Km for phenylpyruvate with this modified enzyme; however, there is also a 2-fold decrease seen in
kcat. The kcat for OAA
with this cyclohexyl-modified enzyme is less than 2% that of the
native enzyme, and the 3-fold increase in Km leads to a greater than 200-fold decrease in
kcat/Km for OAA. To further
assess the role of an introduced aromatic group in substrate
binding the R81C MDH mutant was modified with several substituted
benzyl reagents. Introduction of either 4-fluoro- or 4-amino
substituent on the benzyl group leads to a decrease in
kcat, with OAA as the substrate, to 10-20% of
the native enzyme with no effect on Km. Modification
with 4-nitrobenzyl results in a more dramatic decrease in
kcat, to less than 1% that of the native
enzyme. Each of these enzymes that have been modified with
p-substituted benzyl groups have kcat
values for phenylpyruvate that are only 20-50% that of the unmodified
R81C enzyme, with Km values that are increased by up
to a factor of 7 (Table II).
These modified enzymes are each fairly specific for phenylpyruvate;
pyruvate is not a substrate. Neither medium chain alkyl keto acids
(e.g. 2-ketocaproate) nor a homologous aryl keto acid (phenylglyoxalate) are substrates for these R81C-modified enzymes when
examined at concentrations up to 100 mM.
 |
DISCUSSION |
Substrate Specificity--
Replacement of the -carboxyl group
of OAA with a hydroxyl group (hydroxypyruvate) leads to a modest
decrease in kcat but a dramatic increase in
Km by nearly 3 orders of magnitude. Substitution of
a phenyl group at this substrate position has no additional deleterious
effects, with native MDH preferring OAA as a substrate over
phenylpyruvate by a factor of 2200. Removal of the arginine (Arg-81)
that is proposed to interact with the -carboxyl group of OAA results
in a decline in this substrate preference to 200-fold with a thiol at
this position and to only 100-fold when an aromatic site chain
(phenylalanine) is introduced by site-directed mutagenesis. The
presence of a positively charged guanido group discriminates against
the binding of an aromatic substrate like phenylpyruvate or even a
polar functional group such as hydroxyl and its removal appears to
relieve some of this discrimination. Replacement of this functional
group with an appropriately selected alkyl or aryl residue has the
potential to dramatically enhance the recognition of this alternative
aromatic substrate.
Incorporation of either a straight chain or a branched chain alkyl
group at this position by chemical modulation of the introduced thiolate leads to a further decrease in the selectivity for the physiological substrates and against the aromatic alternative. Modification of R81C with benzyl bromide results in an enzyme form that
still favors OAA as a substrate but now only by a factor of 17, and the
cyclohexyl-modified enzyme has only a 6-fold preference for OAA over
phenylpyruvate as measured by
kcat/Km criteria. This is a
370-fold decrease in the original substrate discrimination against
phenylpyruvate by MDH. However, although the
kcat/Km values for
phenylpyruvate have improved relative to those for OAA, the
kcat values for this substrate have actually
been reversed with the modified enzymes. When these substrates are
compared by kcat criteria, phenylpyruvate is now
the better substrate by nearly 8-fold in both the cyclohexyl- and the
benzyl-modified enzymes. By comparison, the replacement of an entire
loop in the binding site in LDH was required to generate an altered
enzyme in which phenylpyruvate is the preferred substrate. The best
enzyme form that has been produced from LDH through the insertion of four additional amino acids and substitutions at several other positions in this mobile loop has a
kcat/Km for phenylpyruvate that is 1700 times better than that for pyruvate (8). However, in this
case, the reversal in specificity was achieved exclusively as a
consequence of a dramatic decrease in
kcat/Km for pyruvate,
with no enhancement of the kinetics for phenylpyruvate. Despite the
improvement in aromatic substrate selectivity, the kcat/Km for phenylpyruvate
actually decreased by a factor of 2 in this altered LDH compared with
the native enzyme. With MDH, the introduction of an aromatic benzyl
group into the active site results in a 10-fold decrease in
kcat/Km for OAA and a
corresponding 10-fold increase for phenylpyruvate.
The improvement in kcat/Km
that has been achieved for phenylpyruvate as a substrate upon
modulation at a single position in MDH is unexpected in light of the
more stringent substrate specificity of MDH compared with LDH. Unlike
MDH, LDH can already utilize a range of straight and branched chain
keto acids as reasonable alternative substrates, and this specificity
can be further broadened by the mutagenic replacement of a single
active site glutamine (20). Substitution of an arginine at this
position leads to a shift of 7 orders of magnitude in the specificity
of LDH from its physiological substrate pyruvate to OAA with both a
dramatic decrease in the specificity for pyruvate and a corresponding
increase in that for OAA (21). However, attempts to carry out the
complimentary study, the conversion of MDH to an LDH, have been
less successful. Replacement of the corresponding arginine in MDH with
a glutamine results in a decrease of 5 orders of magnitude in
kcat/Km for OAA, with some
improvement but no reversal in the specificity for pyruvate (10).
Aromatic Substituent Effects--
If the improvement in
specificity for phenylpyruvate with MDH is a consequence of binding
interactions between the introduced aromatic ring at position 81 and
the substrate aromatic ring, then substrate binding should be sensitive
to modulations at this introduced ring. To examine this potential
interaction several substituents were introduced at the para-position
of the benzyl ring. These included the electron withdrawing 4-fluoro
and 4-nitro groups and the electron donating 4-amino group. The
expectation was that if there is an interaction between these aromatic
rings, then altering the electron density of the benzyl ring should
affect this interaction. Some kinetic changes are observed with the
introduction of these substituents. Modification of MDH with a
4-aminobenzyl group leads to a 10-fold decrease in
kcat/Km both for OAA and for
phenylpyruvate and, therefore, virtually no change in substrate
selectivity. In contrast, substitution of a 4-fluorobenzyl group
results in an 8-fold shift in preference toward phenylpyruvate, and
placing a 4-nitrobenzyl group in this position leads to a greater than
100-fold shift in preference. These specificity shifts do not strictly
correlate with changes in electron density of the introduced benzyl
ring and must reflect additional steric and orientation effects that
will require high resolution structural mapping to understand.
Structural Basis for the Specificity Changes--
It is not
immediately obvious from the structure of the native enzyme (5) how MDH
can accommodate phenylpyruvate as an alternative substrate. In this
structure the enzyme active site contains two arginyl residues (Arg-81
and Arg-153) that interact with two of the carboxyl groups of a bound
citrate molecule (Fig. 1). It is proposed
that these residues are the binding groups that the enzyme uses to
orient OAA by electrostatic interactions with the - and -carboxyl
groups of the substrate (5). Removal of the positively charged guanido
group of Arg-81 by site-directed mutagenesis results in a 3-6-fold
improvement in the Km for phenylpyruvate. However,
an examination of the active site structure of MDH does not reveal any
hydrophobic pockets that the enzyme could use to accommodate the phenyl
ring of this alternative substrate. To examine any potential
interactions the substrates phenylpyruvate and NAD have been modeled
into the MDH structure and energy minimized. This modeled structure
shows a potential -stacking interaction between the aromatic ring of
phenylpyruvate and the nicotinamide ring of NAD that could account for
some of the binding affinity for this alternative substrate (Fig.
2A). Interestingly, if the
same ternary complex is modeled into the benzyl-modified R81C mutant,
the introduced benzyl ring joins this -stack to sandwich the
substrate phenyl ring with the nicotinamide ring (Fig. 2B).
This structure would be expected to further stabilize the binding of
phenylpyruvate and could explain the 130-fold improvement in substrate
specificity relative to OAA. Replacement of this aromatic functional
group at position 81 with a cyclic alkyl group leads to a 6-fold
decrease in the specificity of this modified enzyme for phenylpyruvate,
presumably because of the loss of aromatic stabilization in this enzyme
form.

View larger version (146K):
[in this window]
[in a new window]
|
Fig. 1.
A picture of the active site of MDH. The
catalytic His-177 and Asp-150 are annotated, along with the
substrate-binding residues Arg-81 and Arg-153. The structure was
determined with NAD and citrate bound in the active site (5).
|
|

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 2.
Molecular model of phenylpyruvate and
NAD+ bound at the active site of the R81C mutant of MDH
(A) and the benzyl-modified R81C mutant
(B). The images were created by using Sybyl
(version 6.5) and were energy minimized.
|
|
 |
ACKNOWLEDGEMENTS |
We thank Dr. Norbert Furumo (Eastern Illinois
University) for providing a plasmid containing the mdh gene
and Dr. Greg Farber (Penn State University) for helpful
discussions on the MDH structure.
 |
Addendum |
A preliminary structure of the R81F mutant of MDH
has just been determined in the absence of
substrates.2 This structure
is essentially identical to that of the native enzyme (5), except for a
disordered loop that includes the site of mutation. This new structure
confirms the local nature of any structural perturbations that might
have occurred among this group of modified MDHs.
 |
FOOTNOTES |
*
This work was supported by National Science Foundation Grant
MCB-9814455.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Present address: University of Wisconsin, Dept. of Biochemistry,
Madison, WI 53706.
§
To whom correspondence should be addressed: Dept. of Chemistry,
University of Toledo, 2801 W. Bancroft St., Toledo, OH 43606. Tel.:
419-530-1582; Fax: 419-530-1583; E-mail:
ron.viola@utoledo.edu.
Published, JBC Papers in Press, July 27, 2000, DOI 10.1074/jbc.M003652200
2
M. Rynkiewicz and R. E. Viola, unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
OAA, oxaloacetate;
LDH, lactate dehydrogenase;
MDH, malate dehydrogenase.
 |
REFERENCES |
| 1.
|
Yoshimura, T.,
Soda, K.,
Matsushima, Y.,
Tanizawa, K.,
Sung, M. H.,
Yamauchi, T.,
Wakayama, M.,
and Esaki, N.
(1990)
J. Biochem. (Tokyo)
108,
699-700
|
| 2.
|
Planas, A.,
and Kirsch, J. F.
(1991)
Biochemistry
30,
8268-8276
|
| 3.
|
Smith, H. B.,
and Hartman, F. C.
(1988)
J. Biol. Chem.
263,
4921-4925
|
| 4.
|
Dhalla, A. M.,
Murtaza, B. L.,
Alibhai, F.,
Yost, K. J.,
Hemmingsen, J. M.,
Atkins, W. M.,
Schineller, J. B.,
and Villafranca, J. J.
(1994)
Protein Sci.
3,
476-481
|
| 5.
|
Hall, M. D.,
Levitt, D. G.,
and Banaszak, L. J.
(1992)
J. Mol. Biol.
226,
867-882
|
| 6.
|
Grau, U. M.,
Trommer, W. E.,
and Rossmann, M. G.
(1981)
J. Mol. Biol.
151,
289-307
|
| 7.
|
Goward, C. R.,
and Nicholls, D. J.
(1994)
Protein Sci.
3,
1883-1888
|
| 8.
|
Wilks, H. M.,
Moreton, K. M.,
Halsall, D. J.,
Hart, K. W.,
Sessions, R. D.,
Clarke, A. R.,
and Holbrook, J. J.
(1992)
Biochemistry
31,
7802-7806
|
| 9.
|
el Hawrani, A. S.,
Sessions, R. B.,
Moreton, K. M.,
and Holbrook, J. J.
(1996)
J. Mol. Biol.
264,
97-110
|
| 10.
|
Nicholls, D. J.,
Miller, J.,
Scawen, M. D.,
Clarke, A. R.,
Holbrook, J. J.,
Atkinson, T.,
and Goward, C. R.
(1992)
Biochem. Biophys. Res. Commun.
189,
1057-1062
|
| 11.
|
Hall, M. D.,
Levitt, D. G.,
McAllister-Henn, L.,
and Banaszak, L. J.
(1991)
J. Mol. Biol.
220,
551-553
|
| 12.
|
Wright, S. K.,
Zhao, F. J.,
Rardin, J.,
Milbrandt, J.,
Helton, M.,
and Furumo, N. C.
(1995)
Arch. Biochem. Biophys.
321,
289-296
|
| 13.
|
Cleland, W. W.
(1967)
Adv. Enzymol.
29,
1-32
|
| 14.
|
Bradford, M.
(1976)
Anal. Biochem.
72,
248-253
|
| 15.
|
Tarragona-Fiol, A.,
Eggelte, H. J.,
Harbron, S.,
Sanchez, E.,
Taylorson, C. J.,
Ward, J. M.,
and Rabin, B. R.
(1993)
Protein Eng.
6,
901-906
|
| 16.
|
Jones, D. H.
(1993)
in
PCR Protocols: Current Methods and Applications
(White, B. A., ed)
, pp. 269-276, Humana Press, Totowa, NJ
|
| 17.
|
Schindler, J. F.,
and Viola, R. E.
(1996)
J. Prot. Chem.
15,
737-742
|
| 18.
|
Ellman, G. L.
(1959)
Arch. Biochem. Biophys.
82,
70-77
|
| 19.
|
Wright, S. K.,
and Viola, R. E.
(1998)
Anal. Biochem.
265,
8-14
|
| 20.
|
Nicholls, D. J.,
Davey, M.,
Jones, S. E.,
Miller, J.,
Holbrook, J. J.,
Clarke, A. R.,
Scawen, M. D.,
Atkinson, T.,
and Goward, C. R.
(1994)
J. Prot. Chem.
13,
129-133
|
| 21.
|
Clarke, A. R.,
Atkinson, T.,
and Holbrook, J. J.
(1989)
Trends Biochem. Sci.
14,
145-148
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. Madern, X. Cai, M. S. Abrahamsen, and G. Zhu
Evolution of Cryptosporidium parvum Lactate Dehydrogenase from Malate Dehydrogenase by a Very Recent Event of Gene Duplication
Mol. Biol. Evol.,
March 1, 2004;
21(3):
489 - 497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Wright and R. E. Viola
Alteration of the Specificity of Malate Dehydrogenase by Chemical Modulation of an Active Site Arginine
J. Biol. Chem.,
August 10, 2001;
276(33):
31151 - 31155.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K. Bell, H. P. Yennawar, S. K. Wright, J. R. Thompson, R. E. Viola, and L. J. Banaszak
Structural Analyses of a Malate Dehydrogenase with a Variable Active Site
J. Biol. Chem.,
August 10, 2001;
276(33):
31156 - 31162.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|